Gen-Probe Rises On FDA License, AVI BioPharma Drops On Negative Results
The Nasdaq Biotech Index (NBI) gained more than 2% as biotech generally had a good day on Wallstreet.
Gen-Probe Inc (GPRO) shares rose more than 7% to $47.62 as the company announced it has recieved an FDA license to market the Semi-Automated PROCLEIX System, which is capable of screening donated blood. PROCLEIX has been approved for marketing outside the United States since 2004.
AVI BioPharma (AVII) shares lost more than 7% to $3.18 as its Neugene antisense compound AVI4065 for hepatitis C did not meet its endpoint for therapeutic efficacy. The company will modify the protocols to increase the dosage in further studies.
_
The Nasdaq Biotech Index (NBI) gained more than 2% as biotech generally had a good day on Wallstreet.
Gen-Probe Inc (GPRO) shares rose more than 7% to $47.62 as the company announced it has recieved an FDA license to market the Semi-Automated PROCLEIX System, which is capable of screening donated blood. PROCLEIX has been approved for marketing outside the United States since 2004.
AVI BioPharma (AVII) shares lost more than 7% to $3.18 as its Neugene antisense compound AVI4065 for hepatitis C did not meet its endpoint for therapeutic efficacy. The company will modify the protocols to increase the dosage in further studies.
_
posted by Nico at
7:43 PM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home